Abstract
The value of thalidomide-dexamethasone was assessed in 26 consecutive, previously untreated patients with multiple myeloma of high tumor mass. All showed Hgb < 8.5 g/dL, serum calcium > 11.5 mg/dL, or both. The response rate was 73%, frequency of early death < 3 months was 5%, projected median survival was 30 months, and projected median remission time was 25 months. There were no occurrences of grade 3 or 4 neutropenia or thrombocytopenia, so that serious infection occurred in only 12% of patients. Thalidomide-dexamethasone was useful for these patients with advanced disease because of the high response rate and acceptable survival, with a low frequency of serious complications.
Original language | English (US) |
---|---|
Pages (from-to) | 194-197 |
Number of pages | 4 |
Journal | American journal of hematology |
Volume | 79 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2005 |
Keywords
- Dexamethasone
- Multiple myeloma
- Thalidomide
ASJC Scopus subject areas
- Hematology